ARTEMIS TECHNOLOGY
» advancing prenatal testing
Our technology will provide women with a simple, non-invasive, and accurate alternative to testing methods available today. With a single blood draw early in pregnancy, our test will provide valuable information without risk to the mother or her fetus.
With our proprietary microfluidic technology, we successfully and reliably recover intact nucleated red blood cells (nRBCs) from maternal blood samples. In the laboratory our device gently separates these rare cells of interest from the billions of contaminating background cells. The result is an unparalleled recovery of intact nRBCs that provide important clinical information.
These rare nRBCs are present in the mother’s blood throughout pregnancy, even in the early stages, and reveal a wealth of information regarding the well-being of both the mother and fetus. Pioneering work by Diana Bianchi, MD and colleagues has shown the significance of these cells in the development of a non-invasive prenatal test. Unlike fragments of DNA, these intact cells provide a complete genetic picture with the highest confidence of fetal origin.
Working in collaboration with leading research and clinical institutions, we have developed cutting edge technology that we believe will transform the field of prenatal testing.
» new clinical guidelines in prenatal testing
Our first product is a simple, non-invasive approach for early prenatal screening for fetal chromosomal abnormalities. Recent guidelines in clinical care from the American College of Obstetrics and Gynecology (ACOG) recommend that all pregnant women should be offered prenatal screening for fetal abnormalities, with emphasis on early non-invasive testing options. For most women, early testing provides reassurance that the pregnancy is developing normally.
top
|
